Zambon it’s amultinational pharmaceutical company founded in 1906 in Vicenza, whose history is based on the values of an Italian family committed to innovating treatment and care to improve patients' lives. It employs over 2,700 people worldwide, is present in 23 countries in Europe, America and Asia, and has production plants in Italy, France, Switzerland, China and Brazil.
Thanks to its innovative and high-quality products marketed in 87 countries, Zambon S.p.A. recorded a turnover of 885 million euros in 2024. Alongside the three traditional therapeutic areas – respiratory system diseases, urinary tract infections e pain management – Zambon is committed to the development of therapies for neurodegenerative diseases like Parkinson's and for rare conditions like cystic fibrosis, BOS (Bronchiolitis Obliterans Syndrome), linked to the significant acquisition in 2019 of Breath Therapeutics, and non-cystic fibrosis bronchiectasis (NCFB).
